dea

US Biotech Accuses DEA of Stalling Innovation In an era where strengthening domestic manufacturing and supply chains, particularly for critical pharmaceuticals, has become a national priority, a significant hurdle is allegedly emerging within the very agencies tasked with regulating controlled substances. The Drug Enforcement Administration’s (DEA) Diversion Control Division is being highlighted as a major…

The U.S. Drug Enforcement Administration (DEA) is reportedly grappling with significant internal and legal challenges, including what some sources describe as a “constitutional crisis” stemming from issues within its Administrative Law Judge (ALJ) system. This comes amid escalating legal action from MMJ BioPharma Cultivation, which alleges the federal agency has deliberately obstructed its crucial medical…

A recent administrative ruling by a Drug Enforcement Administration (DEA) judge against a company seeking to develop pharmaceutical-grade cannabinoid therapies has ignited a significant legal challenge, potentially forcing a constitutional showdown in federal court. Chief Administrative Law Judge John J. Mulrooney II of the DEA issued a ruling described by the affected company, MMJ BioPharma…